Stocks and Investing Stocks and Investing
Thu, November 7, 2019
Wed, November 6, 2019

Andrew Berens Maintained (BPMC) at Buy with Decreased Target to $108 on, Nov 6th, 2019


Published on 2024-10-26 17:53:34 - WOPRAI, Andrew Berens
  Print publication without navigation


Andrew Berens of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Decreased Target from $109 to $108 on, Nov 6th, 2019.

Andrew has made no other calls on BPMC in the last 4 months.



There are 4 other peers that have a rating on BPMC. Out of the 4 peers that are also analyzing BPMC, 2 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Konstantinos Aprilakis of "Deutsche Bank" Downgraded from Strong Buy to Hold and Decreased Target to $75 on, Tuesday, October 29th, 2019
  • Christopher Raymond of "Piper Sandler" Initiated at Hold and Held Target at $85 on, Thursday, August 29th, 2019


These are the ratings of the 2 analyists that currently disagree with Andrew


  • Andrew Fein of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $100 on, Thursday, October 3rd, 2019
  • Joel Beatty of "Baird" Initiated at Buy and Held Target at $120 on, Friday, July 19th, 2019

Contributing Sources